Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

Medicare does not pay for GLP-1 for obesity

Coverage for GLP-1s for obesity treatment is limited. It's barred under Medicare, and it's only covered under Medicaid in 13 states as of January 2026, since states can choose whether to cover weight-loss drugs under Medicaid. Coverage with private insurers also remains limited.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Weight Watchers began offering access to GLP-1 weight loss medications in 2023 after losing more than 1.5 million members over the previous two years.

The rise of telemedicine: A post-pandemic analysis

Before COVID-19, telemedicine remained on healthcare's periphery; however, the pandemic thrust it into the limelight, transforming how we approach medical care. This comprehensive review published by Press Ganey dives deep into the evolution,...

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva

Scientists studying the barely-there feeding frequency of the Gila monster found its saliva had a hormone regulating blood sugar and appetite. Further research revealed this hormone resembled a human one known as GLP-1, giving rise to the modern wave of diabetes and weight-management drugs.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Men are flocking to hundreds of new online testosterone clinics for low T prescriptions

Many primary care clinicians may not be familiar with testosterone testing protocols and treatments, but online testosterone clinics are proliferating, with names like DudeMeds. COVID-era restrictions loosened remote prescribing rules, allowing them to expand online widely, though those more lenient prescribing policies are slated to expire in December 2026 unless they're renewed. (Some users may experience a paywall.)

Virtual care—telehealth—is a significant component of concierge medicine

Telehealth—a central plank of concierge medicine—can widen the gap between the rich and the poor since lower-resource individuals may have less access to technology and encounter other access issues.

Can you microdose GLP-1 agonists like Ozempic?

GLP-1 agonists like Ozempic can help with weight loss, diabetes, and anti-inflammation. For some users, normal doses are too much. So, they've started "microdosing"—taking a smaller amount than the lowest increment of the drug available. While not yet backed by clinical trials, some doctors observed positive effects for certain people.

Hormone and peptide compounds imported from China soared in 2025

US customs data indicates that these imports doubled to $328M in the first three quarters of 2025, from $164M in the same period of 2024. The imports include GLPs, among other products. (Some users may experience a paywall.)

Pharmaceutical companies can use ChatGPT to improve drug development

Moderna has incorporated the tool into its workflows to accelerate analysis and identify optimal drug dosage from clinical data. The company's legal team also uses a custom GPT—Contract Companion—to break down and summarize contracts quickly.

Overmedication has put type 2 diabetics at risk of low blood sugar

Type 2 diabetics in the US risk dying from low blood sugar, an epidemic traced to a decades-old, multi-million-dollar drug industry campaign encouraging an average blood sugar level below 7%. Contemporary research correlated such levels with reduced risk of eye, nerve, and kidney damage and increased hypoglycemia risk.

The promises and perils of using at-home genetic tests for your health

A primer on genetic testing, personalized medicine, and the promise of pharmacogenomics–the use of genetics to predict an individual's response to a drug.

Digital healthcare is helping emerging economies

In a world that is rapidly becoming more digitized, low and middle-income countries (LMICs) are trailblazing a path to cohesive digital healthcare ecosystems. This article from McKinsey & Company analyzes the different digital healthcare strategies...

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

Private equity's expansion into healthcare has been criticized for raising patient medical costs

Between 2000 and 2018, PE's total investment in healthcare ballooned from $5B to $100B. While healthcare systems originally began consolidating as a solution to navigating complex regulations (and to make working with insurance companies easier), research suggests that private equity has both increased patient costs and decreased the quality of care in hospitals and doctors' offices.

Implanted neurotechnology can leave users vulnerable when manufacturers go under

Despite providing relief from neurological conditions, patients are left stranded when the companies that make these devices shut down. The lack of regulation means patients often face technical failure, insurance battles, or risky surgeries to maintain their quality of life.

Black patients are losing their limbs at a rate triple that of other groups due in large part to inequities in diabetes care and management.

Doctors are prescribing social activities—and seeing good results

Physicians, especially in the UK, are asking patients what they enjoy and then prescribing a consistent regimen of doing that type of activity to improve fitness and overall health, including community exercise classes, volunteering, and spending time in nature. This approach may provide better incentives to stick with an activity.

Gestational diabetes occurs when the body can't produce insulin during pregnancy

Globally, pregnant people are increasingly at risk to develop gestational diabetes due to rising maternal ages and obesity rates. The condition is associated with heavier fetal weight, congenital abnormalities, and perinatal mortality, which includes stillbirths and deaths of babies younger than 7 days old.

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

How meal timing factors into health outcomes

The world is trending toward weight gain, a development that comes with a corresponding rise in risk for health conditions, including diabetes and heart disease. This article explores how meal timing has become a factor in nutrition and weight maintenance.

Learn about a new schizophrenia healthcare model that's making a difference

Schizophrenia used to be considered a progressive disease that was beyond a patient's ability to manage. This article gives an in-depth look at OnTrackNY, a New York-based program that empowers patients to define the goals of their own treatment for psychotic disorders. At the time of this 2022 article, it consisted of 25 affiliate clinics and hospitals in 14 New York counties, with another seven sites then slated to begin offering services in 2023.

Two festival-goers were hospitalized after receiving peptide injections, raising questions

Investigative journalism shop ProPublica wrote about two people who became extremely ill following antiaging peptide injections. Authorities were examining whether the individuals were sickened by an infection, contamination related to the injections, or an issue with the medication itself, according to documents obtained by the journalists at ProPublica.

Dietary supplements are regulated like foods

This hour-long 2016 documentary from Frontline, the Canadian Broadcasting Corporation, and The New York Times examined the safety of dietary supplements. It noted that this then-$30B industry (it's at least doubled since then) suffers from irregularities and impurities. It warned that many Americans are unaware of the lack of regulatory oversight over these products.

The spread of fraudulent stem cell treatments

All the coverage of research into promising (but often unproven) medical treatments involving stem cells has created conditions allowing some people to engage in activities regulators describe as scams. As this news article explains, attorneys general in at least seven states have taken legal action against businesses that promised (costly) stem cell treatments but allegedly engaged in fraud.

Government watchdog says nursing homes are inappropriately diagnosing schizophrenia

The Department of Health and Human Services Office of Inspector General said in a March 2026 report that nursing homes are incorrectly diagnosing their residents with schizophrenia to mask the facilities' misuse of antipsychotic medications. The drugs, the report states, are being widely used to make staff members' jobs easier and to keep nursing home quality measures high—since antipsychotic use for schizophrenia wouldn't be counted against the facility. (PDF)

The US FDA recently tried to regulate the expanded prenatal genetic tests

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.

Inhalers, antihistamines, immunotherapy, and more have made allergies a multimillion-dollar market

Market research suggests that the allergies market will continue to grow in the years ahead as the number of allergy diagnoses increases, identifying new patients. Areas of growth include the increasing interest in immunotherapies designed to retrain the immune system through regular exposure to potential allergens via injections and under-the-tongue medical formulations, among other approaches.

Most Americans are now dying at home, reversing 20th century trends

For most of the 21st and 20th centuries most Americans died in hospital settings. But in 2016, home-based deaths overtook hospitals; most Americans are now dying at home, likely fueled by individual preferences to die at home or to receive at-home palliative care.

Support groups can offer insights into current and potential treatments

Beyond connecting with patients with similar experiences, support groups can also become centers for advocacy and for sharing research advances and medical experiences, including potential side effects from novel therapies or clinical trials.

Deepfake videos impersonating real doctors are spreading false medical advice

More than 100 videos, found primarily on Instagram and TikTok in August 2025, promoted products related to beauty, wellness and weight loss. While TikTok removed 94% of content violating its policies on AI-generated content, these deepfakes were watched and shared before removal, undermining public trust in medicine.

Read the Surgeon General's 2023 loneliness report claiming loneliness is an epidemic

This report details the specific health threats linked with loneliness, including that loneliness and social isolation can increase the risk of premature death by nearly 30%. Loneliness lowers our capability to mount an effective immune response to viruses and respiratory illness, can cause chronic inflammation on par with physical inactivity, and increases the risks for anxiety, depression, dementia, heart disease and stroke.

Explore an animated list of nine scientific breakthroughs funded by NASA, the NSF, and the NIH

Among the technologies made possible by the National Science Foundation and the National Institutes of Health were the CAPTCHA digital puzzles to block bots from accessing sites, the set of diabetes and obesity drugs that fall under the umbrella of GLP-1 receptor agonists, and various cordless appliances, including the handheld vacuum cleaner. (Some readers may experience a paywall.)

Freestanding emergency departments are growing increasingly common

These satellite emergency rooms, though not yet approved in all states, are helping meet the need for emergency services beyond a hospital setting. But from an insurance perspective, they are considered emergency rooms—not urgent care. Freestanding emergency rooms grew tenfold from 2001 to 2016.

BNPL has 19th-century roots, but the pandemic made it mainstream

The modern BNPL model didn't take off until the COVID-19 pandemic, when consumers were stuck at home and lockdowns forced them to shop online rather than in person. The number of US BNPL loans grew more than tenfold from 2019 (16.8 million) to 2021 (180 million), according to a Consumer Financial Protection Bureau report.

How Gleevec transformed leukemia treatment and cancer research

An outline of the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginning of precision medicine.

Insurance denials prevent lifesaving care for patients with eating disorders

A patient living with anorexia nervosa was told by her insurance company that she wasn't sick enough to receive needed care. Her experience highlights how some insurers across Washington state focus on less useful metrics like body mass index and weight to gauge sickness instead of psychiatric symptoms that may better illustrate the urgency of receiving care.

Severe cases of food poisoning have doubled even as food recalls dropped

Food recalls were down in 2024 by 5% as compared to 2023. But some researchers suspect that’s just because there were fewer inspections or fewer people reporting illnesses: Hospitalizations from food poisoning more than doubled during that same period, from 230 to 487, and deaths rose from 8 to 19.